Full Breakdown
AI-Designed Lung Drug Shows Early Reversal of Aging Markers
9/8/2026, 12:01:58 PM
Study Design and Findings
Insilico Medicine, a Hong-Kong-listed artificial-intelligence drug-discovery company, reported that its experimental lung-disease therapy rentosertib reduced biological age in a mid-stage trial. The Phase 2 study enrolled 42 participants with idiopathic pulmonary fibrosis and measured six independent aging clocks—tools developed by Insilico, Harvard University, Peking University and other collaborators that estimate cellular function rather than chronological age. Patients receiving rentosertib experienced an average decline of up to six years in biological age after four weeks, while those on placebo showed little change. The magnitude of the reduction lessened later in the trial, and the analysis was published in *Nature Biotechnology*.
Implications for Anti-Aging Research
The results suggest that a drug originally intended for a chronic lung condition can also modulate biomarkers linked to aging. Longevity researchers have long pursued repurposing existing medicines, but novel anti-aging candidates have frequently failed. Rentosertib’s performance provides a template for evaluating other compounds, especially as the pharmaceutical sector shows growing interest following the broader success of GLP-1 agents. Insilico plans to apply similar aging-clock analyses to at least half of its pipeline, aiming to compress development timelines and identify targets that may address multiple age-related diseases.
Official Perspectives
He noted that regulatory pathways for an indication expressly labeled “aging” do not currently exist, but the data could support future prescribing of rentosertib for age-related conditions once it gains approval for its primary indication.
Future Plans
Insilico intends to continue the Phase 2 trial, which also evaluates rentosertib’s efficacy against idiopathic pulmonary fibrosis, and to conduct comparable aging-clock assessments for additional candidates in its portfolio. The company’s approach underscores the potential for AI-driven target identification to accelerate the development of dual-use therapies that address both disease-specific and broader aging processes.
